Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
16 Jan 2019 FDA Approves Cabozantinib for Hepatocellular Carcinoma Gastrointestinal cancers - Anticancer agents & Biologic therapy
15 Jan 2019 FDA Approves Longer-acting Calaspargase Pegol-mknl for ALL Haematologic malignancies - Anticancer agents & Biologic therapy
14 Jan 2019 NICE Issues Diagnostics Guidance on Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer Breast cancer - Personalised medicine
11 Jan 2019 FDA Approves Tagraxofusp-erzs for Blastic Plasmacytoid Dendritic Cell Neoplasm Haematologic malignancies - Anticancer agents & Biologic therapy
10 Jan 2019 Spotlight on Digital Medicine Personalised medicine
09 Jan 2019 FDA Approves Pembrolizumab for Merkel Cell Carcinoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
08 Jan 2019 FDA Approves Olaparib for First-line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer Gynaecologic malignancies - Personalised medicine - Anticancer agents & Biologic therapy
07 Jan 2019 FDA Approves Herzuma as a Biosimilar to Herceptin Breast cancer - Anticancer agents & Biologic therapy
21 Dec 2018 EMA Recommends Extension of Indications for Brentuximab Vedotin Haematologic malignancies - Anticancer agents & Biologic therapy
20 Dec 2018 EMA Recommends Granting a Marketing Authorisation for Treosulfan Haematologic malignancies - Anticancer agents & Biologic therapy
19 Dec 2018 EMA Recommends Granting a Marketing Authorisation for Ropeginterferon alfa-2b Haematologic malignancies - Anticancer agents & Biologic therapy
18 Dec 2018 EMA Recommends Extension of Indications for Rucaparib Gynaecologic malignancies - Anticancer agents & Biologic therapy
17 Dec 2018 EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab Anticancer agents & Biologic therapy
15 Dec 2018 Data from the OAK Trial Show Fast Progression Is Not More Common with Atezolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
15 Dec 2018 Pembrolizumab Improves Long-term Overall Survival over Docetaxel in Advanced NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy